Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Comparing and contrasting guidance across the Atlantic

Abstract

This editorial refers to 'European Society of Cardiology/ European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: Practical guidance for use in patients at very high cardiovascular risk', byU. Landmesser et al., on page 2245.